AstraZeneca is a global, innovation-driven biopharmaceutical company specialized in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference to healthcare. We have a culture of innovation, with science at the heart of everything we do. Europe is where most of our R&D efforts are conducted. AstraZeneca Italy focuses primarily on cancer (44,7%), cardiovascular/metabolic disease and diabetes (36,2%), respiratory/inflammation/autoimmunity (12,9%), infections and gastrointestinal diseases (6,2%). We are also deeply involved in projects where we believe we can make the difference: these include a significant presence on rare diseases and orphan drugs. The Company has over 750 employees in the Italian market. It has 64 clinical projects ongoing in high unmet needs areas such as oncology, respiratory, cardiovascular and diabetes. Overall there are 500 centers involved in clinical trials with over 120,000 enrolled patients. Within the AstraZeneca global trials, 2.5% of patients are from Italy, the same percentage of UK, more than Spain, and slightly less than Germany and France. In the last 3 years AstraZeneca Italy has invested almost 20 million euros in clinical research and we are firmly committed in enhancing our presence in the next coming years in light of our promising research pipeline. Current R&D expenditures amounts to EUR 6.3 on clinical trials alone.
Walgreens Boots Alliance (Nasdaq: WBA) is the first global pharmacy-led, health and wellbeing enterprise. The company’s heritage of trusted health care services through community pharmacy care and pharmaceutical wholesaling dates back more than 100 years.Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25 countries and employ more than 415,000 people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with its equity method investments, has more than 18,500 stores in 11 countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with more than 390 distribution centres delivering to more than 230,000 pharmacies, doctors, health centres and hospitals each year in more than 20 countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products.The company’s portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Soap & Glory, Liz Earle, Sleek MakeUP and Botanics.Walgreens Boots Alliance is proud to be a force for good, leveraging many decades of experience and its international scale, to care for people and the planet through numerous social responsibility and sustainability initiatives that have an impact on the health and wellbeing of millions of people.Walgreens Boots Alliance is included in Fortune magazine’s 2019 list of the World’s Most Admired Companies and ranked first in the food and drugstore category. This is the 26th consecutive year that Walgreens Boots Alliance or its predecessor company, Walgreen Co., has been named to the list.